Abstract: The invention provides for methods for treating a hair loss disorder in a subject by administering a Janus Kinase/Signal Transducers and Activators of Transcription inhibitor.

Abstract: Methods for forming a graft copolymer of a poly(vinylidene fluoride)-based polymer and at least one type of electrically conductive polymer, wherein the electrically conductive polymer is grafted on the poly(vinylidene fluoride)-based polymer are provided. The methods comprise a) irradiating a poly(vinylidene fluoride)-based polymer with a stream of electrically charged particles; b) forming a solution comprising the irradiated poly(vinylidene fluoride)-based polymer, an electrically conductive monomer and an acid in a suitable solvent; and c) adding an oxidant to the solution to form the graft copolymer. Graft copolymers of a poly(vinylidene fluoride)-based polymer and at least one type of electrically conductive polymer, wherein the electrically conductive polymer is grafted on the poly(vinylidene fluoride)-based polymer, nanocomposite materials comprising the graft copolymer, and multilayer capacitors comprising the nanocomposite material are also provided.

Abstract: Methods and apparatus for the in vitro modelling of changes that occur on administration of a drug formulation are described, in particular for studying the changes that take place on administration of protein or peptide drug formulations by subcutaneous injection.

Abstract: A method of polymerizing monomer to form polymer at the surface of particulate material, said method comprising: providing a dispersion of said particulate material in a continuous liquid phase, said dispersion comprising a RAFT agent as a stabilizer for said particulate material, and said continuous liquid phase comprising one or more ethylenically unsaturated monomers; and polymerizing said one or more ethylenically unsaturated monomers under the control of said RAFT agent to thereby form polymer at the surface of said particulate material.

Abstract: The present invention includes a novel salt-free water softening method that utilizes an exchange medium (such as a gel exchange polymer, a macroporous exchange polymer, or an inorganic cation exchanger) that is pre-loaded with a polyvalent cation that has low solubility in aqueous phase at nearly neutral pH. The method of the invention does not require use of a sodium salt or mineral acid in the regeneration of the exchange medium.

Abstract: Methods and compositions are provided for treating an individual having cancer. Aspects of the methods include administering to the individual an inhibitor of a non-canonical Notch signaling pathway gene in an amount effective to treat the cancer. Also provided are reagents, devices and kits thereof that find use in practicing the subject methods.

Abstract: A self-healing coating composition for use on metals includes a polyurea, an epoxy ester unsaturated resin, a combination of amine terminated siloxane and epoxy terminated siloxane and an organoclay. The polyurea is a water-soluble, aromatic polyurea and likewise, the epoxy ester is a water-soluble, aromatic epoxy ester. The coating composition is formed in a non-volatile solvent, such as N-Methylpyrrolidone. It can be applied to a metal surface and cured at room temperature to form a coating that is resistant to corrosion. Further the coating self-heals in a manner similar to a chromate coating.

Abstract: The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or an undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration.

Abstract: Systems, methods, and apparatuses can determine and use methylation profiles of various tissues and samples. Examples are provided. A methylation profile can be deduced for fetal/tumor tissue based on a comparison of plasma methylation (or other sample with cell-free DNA) to a methylation profile of the mother/patient. A methylation profile can be determined for fetal/tumor tissue using tissue-specific alleles to identify DNA from the fetus/tumor when the sample has a mixture of DNA. A methylation profile can be used to determine copy number variations in genome of a fetus/tumor. Methylation markers for a fetus have been identified via various techniques. The methylation profile can be determined by determining a size parameter of a size distribution of DNA fragments, where reference values for the size parameter can be used to determine methylation levels. Additionally, a methylation level can be used to determine a level of cancer.

Abstract: A device and method for the collection of sterile specimen samples from the uterus is presented. Also presented is a method of delivering nano-encapsulated drugs to the female reproductive tract to treat pelvic inflammatory disease. The device generally is comprised of an outer cannula over which a cover is provided. A sampler may be positioned within the cannula so that when the sampler is advanced through the cannula, the sampler exits an orifice at one end of the cannula and pierces the cover causing it to retract. In use, the device is positioned within the vagina and once correctly positioned, the sampler is advanced thus piercing the cover and allowing an uncontaminated sample to be taken from the uterus or a drug to be delivered directly into the uterus.

Abstract: The present invention are methods for fabrication of micro- and/or nano-scale adhesive fibers and their use for movement and manipulation of objects. Further disclosed is a method of manipulating a part by providing a manipulation device with a plurality of fibers, where each fiber has a tip with a flat surface that is parallel to a backing layer, contacting the flat surfaces on an object, moving the object to a new location, then disengaging the tips from the object.

Abstract: An end milling apparatus has an end mill and a support member. The end mill has a cutting portion and a non-cutting portion. The support member supports the non-cutting portion in at least one direction toward the periphery of the end mill. The width of the support member as measured in the direction orthogonal to the direction of the center axis of the end mill and to the direction in which the support member is located as viewed from the end mill is smaller than the outer diameter of the end mill.

Abstract: Disclosed are isolated mutant erythropoietin (EPO) polypeptides, functional fragment thereof, nucleic acid encoding such peptides, vectors including such nucleic acids and compositions including such peptides and nucleic acids. The mutant EPO peptides are unique in that they include a substitution at amino acid position number 76, such as a glutamic acid for arginine substitution at position 76. This substitution inhibits erythropoietic activity while retaining their neuroprotection. Also disclosed are methods of treating or inhibiting neuronal degeneration, reducing or inhibiting one or more symptoms associated with neuronal degeneration and/or glaucoma in a subject. The methods include administering a therapeutically effective amount of a isolated mutant erythropoietin EPO polypeptide, an expression vector encoding such a mutant erythropoietin EPO polypeptide, a viral particle including an expression vector, or a composition, thereby treating or inhibiting neuronal degeneration in the subject.

Abstract: Provided is an operating method of a full-bridge sub-module (FBSM)-based modular multilevel converter for HVDC transmission with AC-side voltage boosting. The peak value of the AC-side voltage is increased under a constant DC-link voltage by using FBSM's negative output voltage under steady state, wherein keeping the semiconductor's current rating constant during AC-side voltage boosting is in favor of reducing converter cost by decreasing energy interaction between the upper and lower arms in a leg, and further capacitance value of FBSM's capacitor under a constant capacitor voltage ripple, keeping the RMS value of AC-side current constant during AC-side voltage boosting can effectively improve transmission capacity of the converter while reducing converter cost, and keeping converter transmission capacity constant during AC-side voltage boosting can reduce RMS value of arm currents while reducing converter cost, thereby reducing power loss of FBSMs and improving converter efficiency.

Abstract: The invention relates to intracellular lipid binding proteins that bind retinoids and/or dye ligands and that are modified to transmit or emit light at a variety of different wavelengths.

Abstract: The present invention provides devices and methods for capturing rare cells. The devices and methods described herein can be used to facilitate the diagnosis and monitoring of metastatic cancers.

Abstract: Disclosed are small molecule non-peptidic compounds, as well as methods and compositions for the treatment of angiotensin-related diseases and disorders, including cardiovascular diseases, metabolic diseases, gastrointestinal diseases, renal diseases, inflammatory/autoimmune diseases, neurological diseases, bone marrow diseases and cancer.

Abstract: Biomarkers for abnormal kidney function, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV, and methods for their use in assessing abnormal kidney function are disclosed herein.

Abstract: The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of, gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.

Abstract: A compound having a structure of: